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WOSIKOWSKI, K., JASCHINSKI, F., KORHONEN, H., BRAUN, S., HASENBACH, K., LEO, E. AND JANICOT, M.
Isarna Therapeutics. Munich. Germany (www.isarna-therapeutics.com) BACKGROUND: Transforming Growth Factor beta (TGF-β) proteins are members of a large family of related cytokines comprised of at least 33 members in mammals encoded by different genes, and which regulate a host of activities ranging from embryonic development to tissue homeostasis. The three bona fide TGF-β isoforms (TGF-β1, -β2 and -β3) play critical, pleiotropic roles in the pathophysiology of various human diseases. In cancer, correlations between TGF-β expression, disease stage and clinical parameters have been reported and linked to poor clinical outcome. TGF-β has been associated with a wide range of tumor-promoting processes, including tumor cell invasion and migration, angiogenesis, immunosuppression, as well as tumor stem cell maintenance and protection.
More specifically, the TGF-β2 isoform has been reported to be a key molecular determinant of immunosuppression and invasiveness, and consequently playing a major role in metastasis. Therefore, inhibiting TGF-β2 appears as an attractive therapeutic intervention in Oncology. Based on the sequence of the human TGF-β2 mRNA, we have identified and engineered ASPH_0047, a 17-mer full phosphorothioate LNA-modified antisense oligodeoxynucleotide '4+4' gapmer, which shows potent and selective target mRNA and protein downregulation in various tumor cell-based assays, and promising antitumor activity in animal models.
ASPH_0047
:
5' -CAAAGTATTTGGTCTCC-3'
In preclinical species, ASPH_0047 features plasma and tissue pharmacokinetics profile similar to previously reported profiles for LNA gapmers, strong metabolic stability and long-lasting tissue distribution with marked tissue penetration in liver, kidney and spleen. Preliminary safety assessment of ASPH_0047 in rats and Cynomolgus monkeys upon repeated 30-min infusion consistently points at dose-related stimulation of the immune system in several organs, including accumulation of distended macrophages in lymph nodes, and degenerative renal and liver changes at high doses. 
Figure 1
Downregulation of target TGF-β isoform mRNAs and proteins by the indicated LNA-modified oligonucleotides after gymnotic delivery in human Panc1 pancreatic cancer cells (7 days) Doses Rat : 0, 10, 30, 75 and 150 mg/kg/adm Doses Monkey : 10, 50 and 100 mg/kg/adm 
